Anticancer Activity of Methyl-Substituted Oxaliplatin Analogs

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Molecular Pharmacology

• Publication date

  2012-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/mol.111.077321PMID 22331606PMCID PMC3375001
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes?

  2011cited by this paper
• Multimodal assessment of painful peripheral neuropathy induced by chronic oxaliplatin-based chemotherapy in mice

  2011cited by this paper
• Anticancer Activity of Metal Complexes: Involvement of Redox Processes

  2011cited by this paper
• Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors

  2011cited by this paper
• Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress

  2011cited by this paper
• Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation

  2011cited by this paper
• Oxaliplatin Transport Mediated by Organic Cation/Carnitine Transporters OCTN1 and OCTN2 in Overexpressing Human Embryonic Kidney 293 Cells and Rat Dorsal Root Ganglion Neurons

  2011cited by this paper
• Fresh platinum complexes with promising antitumor activity.

  2010cited by this paper
• {(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): a novel enantiomerically pure oxaliplatin derivative showing improved anticancer activity in vivo.

  2010cited by this paper
• Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway

  2010cited by this paper
• Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.

  2010cited by this paper
• Immunogenic death of colon cancer cells treated with oxaliplatin

  2010influential reference
• Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339

  2010cited by this paper
• Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)

  2010cited by this paper
• Platinum neurotoxicity pharmacogenetics

  2009cited by this paper
• Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature.

  2009influential reference
• Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli

  2009influential reference
• New-generation platinum agents for solid tumors.

  2009cited by this paper
• Oxaliplatin‐induced neuropathy in the rat: Involvement of oxalate in cold hyperalgesia but not mechanical allodynia

  2009cited by this paper
• Unusual DNA binding modes for metal anticancer complexes.

  2009cited by this paper
• A review on oxaliplatin-induced peripheral nerve damage.

  2008cited by this paper
• Resistance against novel anticancer metal compounds: differences and similarities.

  2008cited by this paper
• Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition

  2008cited by this paper
• Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.

  2007cited by this paper
• Novel di- and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination.

  2007cited by this paper
• Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).

  2007cited by this paper
• The resurgence of platinum-based cancer chemotherapy

  2007cited by this paper
• Cellular processing of platinum anticancer drugs

  2005cited by this paper
• Synthesis and structure-activity relationships of mono- and dialkyl-substituted oxaliplatin derivatives.

  2005cited by this paper
• Recognition and processing of cisplatin- and oxaliplatin-DNA adducts.

  2005cited by this paper
• Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage‐gated sodium channels

  2005cited by this paper
• Analysis of anticancer platinum(II)‐complexes by microemulsion electrokinetic chromatography: Separation of diastereomers and estimation of octanol‐water partition coefficients

  2005cited by this paper
• Synthesis, crystal structure and cytotoxicity of new oxaliplatin analogues indicating that improvement of anticancer activity is still possible.

  2004cited by this paper
• Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect.

  2004cited by this paper
• A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

  2004cited by this paper
• Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells

  2004cited by this paper
• The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons.

  2000cited by this paper
• Biotransformations of oxaliplatin in rat blood in vitro

  1999cited by this paper
• Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA.

  1998cited by this paper
• Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.

  1995influential reference
• Intrinsic MDR‐1 gene and P‐glycoprotein expression in human melanoma cell lines

  1994cited by this paper
• Platinum Compounds: a New Class of Potent Antitumour Agents

  1969cited by this paper
• Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode

  1965cited by this paper

• Dehydroacetic acid benzoyl hydrazone complexes of Ni(II) and Pd(II): Synthesis, characterization, computational studies, biomolecular interaction, and dual anticancer–antimicrobial activities

  2026cites this paper
• Anticancer activity of new oxaliplatin analogs with aliphatic glycine ligands

  2026cites this paper
• LA-ICP-TOFMS Imaging Reveals Significant Influence of Cancer Cell Resistance on Oxaliplatin Compartmentalization in the Tumor Microenvironment

  2025cites this paper
• In vitro and In vivo Growth Inhibition and Apoptosis of Cancer Cells by Ethyl 4-[(4-methylbenzyl)oxy] Benzoate Complex.

  2025cites this paper
• Metal-based immunogenic cell death inducers for cancer immunotherapy

  2025cites this paper
• Albumin-targeted oxaliplatin(iv) prodrugs bearing STING agonists

  2025cites this paper
• Structural variations in the trans-carboxylate/chlorido axis that impact the mode of action of Pt(ii) complexes

  2025cites this paper
• Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination.

  2024cites this paper
• Four newly synthesized enones induce mitochondrial-mediated apoptosis and G2/M cell cycle arrest in colorectal and cervical cancer cells

  2024cites this paper
• New hemisynthetic derivatives of sphaeropsidin phytotoxins triggering severe endoplasmic reticulum swelling in cancer cells

  2024cites this paper
• An overview of recent advancements in anticancer Pt(IV) prodrugs: New smart drug combinations, activation and delivery strategies

  2023cites this paper
• Oxaliplatin and its derivatives – An overview

  2023cites this paper
• Multifaceted Roles of Pollen in the Management of Cancer.

  2023cites this paper
• Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs

  2023cites this paper
• Platinum(IV) Derivatives of [Pt(1S,2S-diaminocyclohexane)(5,6-dimethyl-1,10-phenanthroline)] with Diclofenac Ligands in the Axial Positions: A New Class of Potent Multi-action Agents Exhibiting Selectivity to Cancer Cells

  2023cites this paper
• Long non-coding RNA DINO promotes cisplatin sensitivity in lung adenocarcinoma via the p53-Bax axis

  2023cites this paper
• Repurposing FDA-approved drugs against the toxicity of platinum-based anticancer drugs.

  2022cites this paper
• Novel Nickel(II), Palladium(II), and Platinum(II) Complexes with O,S Bidendate Cinnamic Acid Ester Derivatives: An In Vitro Cytotoxic Comparison to Ruthenium(II) and Osmium(II) Analogues

  2022cites this paper
• Influence of Ring Modifications on Nucleolar Stress Caused by Oxaliplatin‐Like Compounds **

  2022cites this paper
• A Rising Interest in the Development of Metal Complexes in Cancer Immunotherapy.

  2022cites this paper
• A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance

  2022cites this paper
• Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future.

  2022cites this paper
• Successes and failures of immunotherapy for gastric cancer.

  2022cites this paper
• Synthesis and spectral studies of lanthanide metal tetraaza macrocyclic complexes

  2021cites this paper
• Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands

  2021cites this paper
• Berberine-photodynamic therapy sensitizes melanoma cells to cisplatin-induced apoptosis through ROS-mediated P38 MAPK pathways.

  2021cites this paper
• A photoactivated Ir(iii) complex targets cancer stem cells and induces secretion of damage-associated molecular patterns in melanoma cells characteristic of immunogenic cell death

  2021cites this paper
• Effect of chirality on the anticancer activity of Pt(II) and Pt(IV) complexes containing 1R,2R and 1S,2S enantiomers of the trans-1,2-diamino-4-cyclohexene ligand (DACHEX), an analogue of diaminocyclohexane used in oxaliplatin.

  2021cites this paper
• A [Pt(cis-1,3-diaminocycloalkane)Cl2] analog exhibits hallmarks typical of immunogenic cell death inducers in model cancer cells.

  2021cites this paper
• Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo

  2021cites this paper
• Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance.

  2021cites this paper
• Thermodynamic Genome-Scale Metabolic Modeling of Metallodrug Resistance in Colorectal Cancer

  2021cites this paper
• Design, synthesis and biological evaluation of dihydro-2-quinolone platinum(IV) hybrids as antitumor agents displaying mitochondria injury and DNA damage mechanism.

  2020cites this paper
• Pharmacokinetics and tissue distribution in rats of a novel anticancer platinum compound LLC-1903

  2020cites this paper
• Synthesis and biological evaluation of new mono naphthalimide platinum(IV) derivatives as antitumor agents with dual DNA damage mechanism

  2020cites this paper
• Recent Advances of Gold Compounds in Anticancer Immunity

  2020cites this paper
• Induction of immunogenic cell death in cancer cells by a photoactivated platinum(IV) prodrug.

  2020cites this paper
• A minimal structural variation can overcome tumour resistance of oxaliplatin: the case of 4,5-dehydrogenation of the cyclohexane ring

  2019cites this paper
• Synergistic antitumor effect of anti‐PD‐L1 combined with oxaliplatin on a mouse tumor model

  2019cites this paper
• A potent aminonaphthalimide platinum(IV) complex with effective antitumor activities in vitro and in vivo displaying dual DNA damage effects on tumor cells.

  2019cites this paper
• Synthesis, Characterization, Cytotoxicity, and Time-Dependent NMR Spectroscopic Studies of (SP -4-3)-Oxalato[(1R ,2R ,4R /1S ,2S ,4S )-(4-trifluoromethyl-cyclohexane-1,2-diamine)]platinum(II)

  2019cites this paper
• An aminophosphonate ester ligand-containing platinum(ii) complex induces potent immunogenic cell death in vitro and elicits effective anti-tumour immune responses in vivo.

  2019cites this paper
• Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis

  2018cites this paper
• Anticancer activity of new imidazole derivative of 1R,2R-diaminocyclohexane palladium and platinum complexes as DNA fluorescent probes

  2018cites this paper
• The potential of antioxidant activity of methanolic extract of Coscinium fenestratum (Goetgh.) Colebr (Menispermaceae)

  2018cites this paper
• Metal Drugs and the Anticancer Immune Response.

  2018cites this paper
• Gadolinium and Platinum in Tandem: Real-time Multi-Modal Monitoring of Drug Delivery by MRI and Fluorescence Imaging

  2017cites this paper
• Autophagy impacts on oxaliplatin-induced hepatocarcinoma apoptosis via the IL-17/IL-17R-JAK2/STAT3 signaling pathway.

  2017cites this paper
• Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models.

  2017cites this paper
• Enhancing the cytotoxic activity of anticancer Pt(IV) complexes by introduction of lonidamine as an axial ligand

  2017cites this paper
• PtI2(DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features.

  2017cites this paper
• Response Profiling Using Shotgun Proteomics Enables Global Metallodrug Mechanisms of Action To Be Established.

  2017cites this paper
• Influence of the Number of Axial Bexarotene Ligands on the Cytotoxicity of Pt(IV) Analogs of Oxaliplatin

  2017cites this paper
• Anticancer metal drugs and immunogenic cell death.

  2016cites this paper
• Synthesis, characterisation and cytotoxicity of [(1,10-phenanthroline)(1R,2R,4R/1S,2S,4S)-4-methyl-1,2-cyclohexanediamine)platinum(II)]2+ (PHEN-4-MeDACH)

  2016cites this paper
• Platinum-based drugs: past, present and future

  2016cites this paper
• Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes.

  2016cites this paper
• Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents.

  2015cites this paper
• Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application

  2014cites this paper
• Synthesis, characterization and cytotoxic activity of novel platinum(II) iodido complexes.

  2014cites this paper
• Novel Oxaliplatin Derivatives with 1‐(Substituted Benzyl)azetidine‐3,3‐dicarboxylate Anions. Synthesis, Cytotoxicity, and Interaction with DNA

  2014cites this paper
• Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands.

  2013cites this paper
• Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery.

  2013cites this paper
• Estudio Teórico de la Reactividad Química y Biológica de Cisplatino y algunos Derivados con Actividad Anticancerosa

  2013cites this paper
• Synthesis and characterization of novel oxaliplatin analogs

  2012cites this paper